scFv(EGFR)-CD28-OX40-CD3zeta CAR-T Lentivirus

The scFv(EGFR)-CD28-OX40-CD3ζ CAR-T lentivirus is a highly advanced gene delivery system designed to modify T cells for targeted immunotherapy. This lentiviral vector is characterized by its efficient and stable transfer of genes to primary human T cells, ensuring the integration of the chimeric antigen receptor (CAR) into the host genome for long-term expression. As a third-generation CAR construct, it possesses a complex intracellular signaling structure, including the major activating domain CD3ζ and two potent co-stimulatory domains CD28 and OX40. The co-inclusion of CD28 and OX40 provides significant advantages over previous generations of CARs; CD28 promotes rapid T cell proliferation and early activation, while OX40 enhances long-term T cell survival, metabolic adaptation, and the formation of memory T cells. This dual co-stimulation significantly improves the persistence and anti-tumor efficacy of CAR-T cells, especially in the complex immunosuppressive microenvironment of solid tumors.

The application of this lentiviral system is primarily focused on the research and development of therapeutic strategies targeting malignancies overexpressing epidermal growth factor receptor (EGFR). EGFR is a key target in oncology because its dysregulation is a hallmark of various aggressive cancers, including glioblastoma, non-small cell lung cancer, and head and neck squamous cell carcinoma. Using these lentiviral particles, researchers can generate highly specific CAR-T cells and evaluate their cytotoxicity against EGFR-positive tumor cells in in vitro experiments and in vivo animal models. In addition to its direct use in therapeutic development, the scFv(EGFR)-CD28-OX40-CD3zeta CAR-T lentivirus is also an important tool for studying mechanisms such as T cell exhaustion, cytokine release syndrome (CRS) models, and the dynamics of T cell infiltration in solid tumors.